Cortechs.ai | Cortechs.ai appoints Dr. Chris Airriess as new CEO

Cortechs.ai appoints Dr. Chris Airriess as new CEO

Industry veteran, Amy Verrinder, named VP of Sales 

(SAN DIEGO) Sept. 1, 2019 — Cortechs.ai is pleased to announce the appointments of its new chief executive officer, Dr. Chris Airriess, and vice president of sales, Amy Verrinder. Both executives have been long-time employees of Cortechs.ai and have contributed fundamentally to the company’s growth.

Dr. Airriess has been part of the Cortechs.ai team for over 12 years, serving as the company’s chief technology officer and chief operating officer. He was a major catalyst in the development of the flagship product, NeuroQuant®, and came to Cortechs.ai with a wealth of experience guiding product and company development.

Before joining Cortechs.ai, Dr. Airriess oversaw the development and growth of therapeutics designed to combat metastatic melanoma and neuromuscular disorders as the chief operating officer for California Stem Cell. He has also served as a director of scientific computing for the Biomedical Informatics Research Network, headquartered at the University of California San Diego. His past leadership roles and extensive technical background make Dr. Airriess a key driver of the growth and expansion of Cortechs.ai.

Amy Verrinder has over 25 years of experience in business development and has been a strong leader in educating clinicians, researchers and business professionals about the power of volumetric imaging. She previously served as Cortechs.ai’ director of sales and national sales director prior to her appointment as vice president of sales. Amy has brought the workflow enhancements and patient outcome improvements, offered by Cortechs.ai’ suite of products, to dozens of major hospitals and independent imaging facilities across the country. Her deep knowledge of the healthcare industry has allowed her to form strong relationships with stakeholders across North America.

Cortechs.ai has several new initiatives for the remainder of 2019 and beyond. Dr. Airriess and Amy Verrinder both look forward to building upon current momentum as the company continues to deploy innovative solutions to aid in the diagnosis of neurodegenerative diseases and, most importantly, to better patient care.

About Cortechs.ai
Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development abnormalities. Please visit cortechs.ai for further information and follow us on Twitter, LinkedIn and Facebook.

###

More Resources

03/20/2026

Quantitative MRI, the McDonald Criteria, and the Future of Multiple Sclerosis Care

MRI is the foundation for diagnosing and monitoring multiple sclerosis (MS)

03/13/2026

Cortechs Cares: Community Impact and Volunteer Efforts in 2025

Cortechs Cares highlights how our team gave back in 2025 through community volunteer efforts, including an Alzheimer’s Walk and holiday toy drive.

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

Scroll to Top